ABCDEFGHIJKLMNOPQRSTUVWXYZAA
1
TopicDateLink
2
Post-Protocol Therapies in Myeloma 4/28/21
https://twitter.com/ManniMD1/status/1387425638278213645?s=20&t=Iw735r2UDlHnL2FvZDNE7Q
3
Studies for desk rejection by editors?5/10/21
https://twitter.com/ManniMD1/status/1391797530707611652?s=20
4
CASSIOPEIA- Dara versus obs as maintenance5/19/21
https://twitter.com/ManniMD1/status/1395194212346388482?s=20
5
Our study on infection risk in myeloma trials6/26/21
https://twitter.com/ManniMD1/status/1408773705530941445?s=20
6
Belantamab and DREAMM2 Trial7/27/21
https://twitter.com/ManniMD1/status/1420204067033280520?s=20
7
Teclistamab in myeloma8/11/21
https://twitter.com/ManniMD1/status/1425463898291859456?s=20
8
A problematic MRD study8/23/21
https://twitter.com/ManniMD1/status/1429799856504115200?s=20
9
Intent to treat versus modified intent to treat in CART8/25/21
https://twitter.com/ManniMD1/status/1430704078837800965?s=20
10
Reporting on quality of life in a selinexor study9/13/21
https://twitter.com/ManniMD1/status/1437620123578163202?s=20
11
CASSIOPEIA, intertia in trial design and enrollment9/14/21
https://twitter.com/ManniMD1/status/1437820068314771460
12
Maintenance in high-risk myeloma9/21/21
https://twitter.com/ManniMD1/status/1440477558844190731?s=20
13
Myeloma Trials I have been excited about9/27/21
https://twitter.com/ManniMD1/status/1442691823927840768?s=20
14
Light Chains in Renal Insufficiency10/5/21
https://twitter.com/ManniMD1/status/1445507511717482506?s=20
15
 MAIA Trial and Post Protocol Therapy10/14/21
https://twitter.com/ManniMD1/status/1448659610315886604?s=20
16
Quads versus Triplets in Myeloma11/21/21
https://twitter.com/ManniMD1/status/1473385527868940290?s=20
17
The FORTE Trial11/30/21
https://twitter.com/ManniMD1/status/1465834971789029377?s=20
18
Promising ASH2021 Studies 12/13/21
https://twitter.com/ManniMD1/status/1470404273678651395?s=20&t=Iw735r2UDlHnL2FvZDNE7Q
19
ASH 21- Flawed studies12/23/21
https://twitter.com/ManniMD1/status/1474236105021026306?s=20
20
Bone Density and MGUS12/25/21
https://twitter.com/ManniMD1/status/1474886818122371078?s=20
21
Melflufen and the OCEAN trial1/13/22
https://twitter.com/ManniMD1/status/1481803179704471555?s=20
22
Reporting of adverse survival from a patient perspective1/31/22
https://twitter.com/ManniMD1/status/1488305598701604866?s=20&t=XLZi6teMwdDpUdXNRCRYuA
23
Surrogacy of an Endpoint, Editorial Decisions, and MRD2/10/22
https://twitter.com/ManniMD1/status/1491955056555356161?s=20&t=sTY1zL3KrzoZ-ntoTx814A
24
What I would say if I consulted for pharma2/23/22
https://twitter.com/ManniMD1/status/1496472579762229249?s=20&t=yCjQDtItfXZgLiS5RH0zwQ
25
Informative Censoring, Medical Writers and Post Protocol Tx3/3/22
https://twitter.com/ManniMD1/status/1499414230436433921?s=20&t=c5w99wt6ArN0IRqCYR3Usw
26
Diagnosis of Plasma Cell Dyscrasias 3/9/22
https://twitter.com/ManniMD1/status/1501616054484668417
27
VTE in Myeloma3/27/22
https://twitter.com/ManniMD1/status/1508246775097790466?s=20&t=9l05mbLVoHtl-CDqA_loYg
28
The highs and lows of twitter4/1/22
https://twitter.com/ManniMD1/status/1509964285924966401?s=20&t=-a8SUoW5P4wJ8gpeVNIoWA
29
Intent of a clinical trial- and the ethics of control arms4/9/22
https://twitter.com/ManniMD1/status/1512918639489417216?s=20&t=5BiMXBgGGqF-dKg9Q-O2mA
30
Contrasting CLL and smoldering myeloma trials4/19/22
https://twitter.com/ManniMD1/status/1516449059384430593?s=20&t=3Rax7-r4EO1VxhbBmT8A8A
31
The PROMISE study and screening for myeloma5/1/22
https://twitter.com/ManniMD1/status/1520793612023480324?s=20&t=oprQ5UPj9kyEgfkwtjSF5Q
32
Shortcomings and musings on MRD5/6/22
https://twitter.com/ManniMD1/status/1522607585550954496?s=20&t=fD1WP0k7v6Wv0nQU-JIoiA
33
Me-too drugs and the curious case of isatuximab5/16/22
https://twitter.com/ManniMD1/status/1526323680719953920?s=20&t=u-Qwy2LnsLCPv5AnkwuvSw
34
The ATLAS study and suitability of PFS as endpoint for maint5/27/22
https://twitter.com/ManniMD1/status/1529966735746555923?s=20&t=YzYnUa-_ifU9fy9isF8HrA
35
Antibiotic de-escalation, non-inferiority trial and per protocol analysis6/17/22
https://twitter.com/ManniMD1/status/1537812935845629955?s=20&t=cysGBt9fM3YYptKSVT7IUw
36
The history of myeloma staging7/8/22
https://twitter.com/ManniMD1/status/1545556424352075776?s=20&t=jCHFqZcBgrzqkn6TzU287A
37
Elo-KRd in myeloma- A PH2 study- Putting in context7/26/22
https://twitter.com/ManniMD1/status/1551973006288621568?s=20&t=gozxAKSQU6l4keDM5kOecQ
38
Intention to treat analysis, Cilta-Cel, ethics and waiting lists8/5/22
https://twitter.com/ManniMD1/status/1555350813890863105?s=20&t=mgNCaqKqZQTt1gyIBQ2-YQ
39
End of life in myeloma, mentorship, and a thread about persevering/getting a paper!8/11/22
https://twitter.com/ManniMD1/status/1557834045345505280?s=20&t=NmVlEODKJdnN3gf5WLS6iQ
40
Where are global myeloma trials ran and drugs approved?8/12/22
https://twitter.com/ManniMD1/status/1558192992590053376?s=20&t=PUohjTmlbmBr_5H-4LnN0w
41
Ten studies from ASH 2022 that influenced my thinking 11/9/22
https://twitter.com/ManniMD1/status/1590440063263182851?s=20&t=tDEM7uLqPx_dZ1l0xGYLCA
42
My favorite BMT CTN trials11/12/22
https://twitter.com/ManniMD1/status/1591459397573939200
43
How do patients with smoldering MM progress?11/18/22
https://twitter.com/ManniMD1/status/1594140708679868416?s=20&t=IqviYwcafvhysoZU3HFdug
44
Looking beyond response rates in Phase 2 single arm trials: Cilta-Cel in China11/24/22
https://twitter.com/ManniMD1/status/1595575470824648705?s=20&t=D7UXeTO9jW78n1JBMPOvaw
45
How to understand cross-over and post-protocol therapy in trials?12/19/22
https://twitter.com/ManniMD1/status/1604951759499464705?s=20&t=NvypTK4UVAcBv-wk3GhBLA
46
Myeloma Recap of 202212/23/22
https://twitter.com/ManniMD1/status/1606372870308958225?s=20&t=1wgqy2OrpcqqX9WUQvLwgA
47
MGUS- 4 Important Facts1/22/23
https://twitter.com/ManniMD1/status/1617297623505063938?s=20&t=q90k8qr6WeqdNNwD_74jVQ
48
Steroids in Myeloma- past present future2/3/23
https://twitter.com/ManniMD1/status/1621617141823979520?s=20&t=VRH_L7aGoyMGHYAn2wWVfQ
49
Transplant in myeloma- the evidence2/8/23
https://twitter.com/ManniMD1/status/1623436847723560960?s=20&t=suRvapx8n4PDpcbAfHCYKA
50
Ide-Cel in myeloma- the first randomized trial 2/10/23
https://twitter.com/ManniMD1/status/1624129917620461568?s=20&t=7tajRMtGZv62ZCln-b2LCQ
51
My first supportive care randomized trial-Budesonide during transplant2/13/23
https://twitter.com/ManniMD1/status/1625155373178191873?s=20&t=-6L31VWWfsIwBJFO_1jOjw
52
Choosing Wisely in myeloma2/18/23
https://twitter.com/ManniMD1/status/1627026822008537090?s=20
53
NICE turning down dara/len/dex for myeloma, some thoughts2/24/23
https://twitter.com/ManniMD1/status/1629142162746245122?s=20
54
PANGEA model as a predictor for myeloma3/1/23
https://x.com/ManniMD1/status/1630974131717144576?s=20
55
Carfilzomib versus bortezomib for myeloma3/21/23
https://twitter.com/ManniMD1/status/1638199981482950658?s=20
56
CRAB and SLiM criteria for myeloma4/14/23
https://twitter.com/ManniMD1/status/1646850409229873152?s=20
57
Activity of myeloma drugs of same class when refractory to drugs of same class4/17/23
https://twitter.com/ManniMD1/status/1647934920017469440
58
How I view PFS and OS in myeloma 5/16/23
https://twitter.com/ManniMD1/status/1658530526062583808?s=20
59
The value of deepening response in myeloma5/31/23
https://twitter.com/ManniMD1/status/1664018384617611264?s=20
60
Cilta-cel in myeloma- what to make of the randomized trial? 6/7/23
https://twitter.com/ManniMD1/status/1666150794750758912?s=20
61
OPTIMUM trial in myeloma- a deep dive6/19/23
https://twitter.com/ManniMD1/status/1670969475922030592?s=20
62
CANDOR and post protocol therapy7/28/23
https://twitter.com/ManniMD1/status/1684952503622987776?s=20
63
Apps and Calculators useful while seeing pts with plasma cell dyscrasias8/1/23
https://twitter.com/ManniMD1/status/1686457316709961729?s=20
64
The status of nutritional epi when contrasted with randomized trials8/22/23
https://twitter.com/ManniMD1/status/1694080496794509323
65
The tragedy of an unethical control arm- the case of melflufen9/1/23
https://twitter.com/ManniMD1/status/1697758868409896977?s=20
66
Are IMiDs really that bad for older patients9/10/23
https://twitter.com/ManniMD1/status/1700979302844833940?s=20
67
FLC Ratio of greater than 100- what is the real risk of progression 9/21/23
https://x.com/ManniMD1/status/1704872741663645904?s=20
68
CANOVA study- and venetoclax in myeloma9/29/23
https://x.com/ManniMD1/status/1707751062072176892?s=20
69
Informative Censoring- and why it matters even for positive trials10/5/23
https://x.com/ManniMD1/status/1709939413953003881?s=20
70
MGUS and Neuropathy- Associations or Not?10/12/23
https://x.com/ManniMD1/status/1712508097095413816?s=20
71
Bispecifics in the real-world, selection bias and short follow-up11/8/23
https://twitter.com/ManniMD1/status/1722437711464931626
72
Ten studies from ASH 2023 that influenced my thinking 11/21/23
https://x.com/ManniMD1/status/1726980328559133028?s=20
73
Myeloma recap 202312/22/23
https://x.com/ManniMD1/status/1738399691082244264?s=20
74
Intent to treat analysis and a legacy of failure of diet in cancer12/31/23
https://x.com/ManniMD1/status/1741539127361945642?s=20
75
Our prospective trial on the natural history of smoldering MM-SPOTLIGHT1/19/24
https://x.com/ManniMD1/status/1748064093230239951?s=20
76
Critical appraisal of the DREAMM7 trial- informative censoring, discontinuation and refractoriness2/13/24
https://x.com/ManniMD1/status/1757416205894504729?s=20
77
Whats the role of diet in cancer? A review of all RCTs3/2/24
https://x.com/ManniMD1/status/1763997899556601900?s=20
78
Smoldering Myeloma- A round-table with only one side?3/7/24
https://x.com/ManniMD1/status/1765771656436584712?s=20
79
My thoughts on cilta-cel approval4/6/24
https://x.com/ManniMD1/status/1776643187920212252
80
4 versus 2 years of zometa- my thoughts4/16/24
https://x.com/ManniMD1/status/1780386714160394357
81
Ten interesting facts about myeloma I teach in clinic5/1/24
https://x.com/ManniMD1/status/1785684554109669595
82
RISS, MASS, c-statistics and staging in myeloma6/12/24
https://x.com/ManniMD1/status/1800879847155327194
83
CASSIOPEIA: A critical interpretation of this trial, and an evaluation of maintenance6/30/24
https://x.com/ManniMD1/status/1807453790565466347
84
GEM-CESAR trial: A critical interpretation and peer review7/23/24
https://x.com/ManniMD1/status/1815784640386621442
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100